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Abstract
Background: Human papillomavirus (HPV) is a necessary cause of cervical cancer. HPV is also responsible for
benign condylomata acuminata, also known as genital warts. We assessed the incidence of genital warts in Germany
and collected information on their management to estimate the annual cost of disease.
Methods: This was a multi-centre observational (cross-sectional) study of genital warts in Germany. Data were
collected from gynecologists, dermatologists, and urologists seeing patients with genital warts between February
and April 2005. The number of patients with new and recurrent genital warts was used to estimate the incidence
in Germany. We assessed resource use for patients with genital warts seen during a two-month period as well as
retrospective resource use twelve months prior to the inclusion visit through a chart review. The mean costs of
treatment of patients with genital warts from third-party payer and societal perspectives were estimated, and the
total annual cost of genital warts was then calculated.
Results: For the incidence calculation 217 specialists provided information on 848 patients and 214 specialists
provided resource use data for 617 patients to assess resource consumption. The incidence of new and recurrent
cases of genital warts was 113.7 and 34.7 per 100 000, respectively, for women aged 14–65 years consulting
gynecologists. The highest incidence was observed in women aged 14–25 years (171.0 per 100 000) for new cases
and in women aged 26–45 years (53.1 per 100 000) for recurrent cases. The sample size for males was too small
to allow a meaningful estimate of the incidence. The mean direct cost per patient with new genital warts was
estimated at 378 euros (95% CI: 310.8–444.9); for recurrent genital warts at 603 euros (95% CI: 436.5–814.5),
and for resistant genital warts at 1,142 euros (95% CI: 639.6–1752.3). The overall cost to third-party payers was
estimated at 49.0 million euros, and the total societal cost at 54.1 million euros, corresponding to an average cost
per patient of 550 euros and 607 euros, respectively.
Conclusion: The societal burden and costs of managing and treating genital warts in Germany are considerable.
A vaccination programme using the quadrivalent human papillomavirus vaccine could provide a substantial health
benefit and reduce the costs associated with genital warts in Germany.
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Background
Human papillomavirus (HPV) is a necessary cause of cer-
vical cancer [1-3]. HPV is also responsible for benign con-
dylomata acuminata, also known as genital warts. It has
been estimated that as many as 75% of the sexually active
population (15–49 years of age) in the US have been
infected with HPV during their lifetime [4]. However,
most HPV-infected individuals eliminate the virus with-
out developing clinical symptoms [5].
To date, nearly 100 HPV types have been molecularly
identified and about 40 of these can infect the anogenital
tract [5-7]. On the basis of their oncogenic potential, most
of these genital HPV types have been classified as high or
low risk for causing cervical cancer. The high-risk types,
especially HPV 16 and 18, are implicated in the develop-
ment of cervical intraepithelial neoplasia and cervical car-
cinoma. The low-risk types (HPV 6, 11, 40, 42, 43, 44, 54,
61, 70, 72, 81, and CP6108) can cause mild cervical dys-
plasia but are rarely associated with severe cervical dyspla-
sia or cervical carcinoma.
It has been reported that low-risk HPV types 6 and 11 are
found in more than 90% of genital warts [8]. Clinically
apparent genital warts affect about 1% (approximately 1.4
million) of the sexually active population (15–49 years)
in the United States [4]. In 2003, new cases of genital
warts accounted for 10% of all diagnoses at genitourinary
medicine clinics in the UK [9]. Another study in the
United Kingdom showed that diagnoses of new genital
warts rose by 4.2% between 2003 and 2004 with the high-
est incidence of genital warts observed in men aged 20–24
years (783 per 100 000) and in women aged 16–19 years
(703 per 100 000) [10].
Genital warts are disfiguring and can have psychosexual
sequelae [11]. Treatment for genital warts includes abla-
tive techniques or topical cytotoxic agents applied by the
patients themselves or their physicians [12]. These treat-
ments have variable response rates (60% to 90%) and can
cause adverse side-effects [12].
The viral origin of genital warts means that this is a poten-
tial target for prophylactic HPV vaccines. Gardasil®, a
quadrivalent HPV vaccine against types 6, 11, 16 and 18,
was approved in 2006 by the European Medicines Agency
as well as by the US Food and Drug Administration for the
prevention of high-grade dysplasia of the cervix or vulva,
cancer of the cervix, and genital warts [13]. The product
license has been granted in many countries, such as US,
Canada, Australia, Mexico, many European countries,
including Germany, and the vaccine will be available
soon in other countries.
Before implementing a HPV vaccination programme, it is
important to understand the burden of illness, including
the morbidity and costs of managing and treating patients
with HPV-associated diseases. Only sparse data are cur-
rently available in Germany for the burden of illness
caused by genital warts. We, therefore, performed a study
to assess the incidence of genital warts, to gather informa-
tion on their management, and to estimate the annual
cost of genital warts in Germany.
Methods
The study was composed of two parts; an epidemiological
survey including aggregated data on genital warts cases to
estimate the incidence of genital warts in Germany and a
chart review to estimate the annual cost for treating geni-
tal warts.
Estimation of the incidence of genital warts
To assess the incidence of genital warts it was estimated
that data from 600 patients would provide a 95% confi-
dence interval (95% CI) of 0.02% to 1.8%, based on an
expected prevalence of 1%. Assuming that urologists,
gynecologists, and dermatologists see on average 10–15,
1–3, and 12 patients with genital warts per month, respec-
tively, (personal communication, Market Research
Agency, Germany) the following sample size of investiga-
tors was required to obtain data on at least 600 patients:
130 gynecologists, 50 dermatologists, and 20 urologists.
To obtain a representative geographical distribution of
these specialists, data from the eight AC Nielsen regions of
Germany were used to calculate the appropriate number
of specialists to be recruited from each region [14]. Physi-
cians participating in this part of the study were asked to
complete a questionnaire to provide information on (i)
the size of their medical practice (total number of patients
seen in the previous year), (ii) the number of patients
aged 14–65 years diagnosed with genital warts in the pre-
vious year, (iii) the average number of patients with geni-
tal warts seen per month, and (iv) the distribution of men
and women aged 14–65 years among patients diagnosed
with genital warts in the previous year. They were also
asked to record information on the patients who con-
sulted them for genital warts between 9 February and 6
April 2005. These patients were classified as new (inci-
dent) cases (diagnosed at the time of the visit) or existing
(previously diagnosed) cases. When information was
available, the latter were further classified as recurrent
(those with previous episodes of genital warts that had
resolved) or resistant (those who had previous episodes of
genital warts that had not resolved with treatment). Since
the study did not include any personal identifiers or direct
patient involvement, ethical approval was not necessary.
The total number of cases of genital warts in Germany was
extrapolated using the number of patients with genitalBMC Infectious Diseases 2008, 8:76 http://www.biomedcentral.com/1471-2334/8/76
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warts per specialist per case type. Case type was defined as
new or existing genital warts with the latter including
recurrent or resistant genital warts. When no information
was available in the medical records to classify the genital
warts as recurrent or resistant, they were classified as
unknown type. The age-specific incidence and incidence
in the at-risk population (14–65 years) were calculated for
women consulting gynecologists. The number of men
included was small and therefore it was not possible to
calculate the incidence of genital warts for men. The total
and age-stratified population data were obtained from
Eurostat [14,15].
Resources consumption and cost analysis
The physicians contacted in the epidemiological survey
were also approached to participate in the cost analysis
study. The specialists were asked to provide data for
patients who consulted for genital warts between 9 Febru-
ary and 6 April 2005 and to record planned resource use
at this inclusion visit and to extract retrospective resource
use from medical records covering the twelve months
prior to the inclusion visit. The goal was to collect resource
use data for at least 600 patients aged between 14 and 65
years, resident in Germany, who consulted a specialist for
genital warts. Data for patients with only papillomatosis
or other condylomata (giant condyloma, keratotic genital
warts, or condyloma plana) were not collected. The
patients were classified by their case type as having new
(incident) or existing genital warts (as defined above). For
existing cases the data were collected both for the inclu-
sion visit and from their medical records for the 12
months prior to the inclusion visit. The data included
demographic and clinical data, information on resource
use (specialists visits, diagnostics, medication, proce-
dures, adverse effects, and hospitalization), and days of
sick leave. For new patients, only data obtained during the
inclusion visit were included as there was no prospective
data collection in this study and there was only a 2-month
inclusion period.
Unit costs for resources
Average unit costs for consultations, diagnostic tests and
treatments (drugs and procedures) related to genital warts
in Germany for 2005 were compiled from the "Einheitli-
cher Bewertungsmassstab" (EBM), the "Gelbe Liste", the
"Gebührenordnung für Ärzte", and the German Diagnosis
Related Groups (Table 1) [16-19]. The cost arising from
loss of work days was based on the gross domestic product
(GDP), the population in Germany in 2004, and the
number of days worked per year (Table 1) [15,20,21].
Statistical analysis of the healthcare cost data
The cost per patient was calculated by multiplying the
units of resources used by the unit costs. The mean cost
per patient for each genital wart type was calculated and
the 95% confidence intervals (95% CI) were obtained
using non-parametric bootstrapping techniques because
the distribution of costs was expected to be skewed. The
impact of patient characteristics (type of patient, type of
wart, gender, infection status and age) and type of special-
ist on the overall costs were evaluated in a multivariable
analysis. An F-test was performed to determine the overall
significance of the model. The significance of each param-
eter in the model was determined using a t-test. Statistical
analyses were conducted using SAS version 8 (SAS Insti-
tute, Inc.).
Estimated total annual cost of genital warts in Germany
The cost of illness for each type of genital warts in Ger-
many was calculated by multiplying the estimated total
number of patients per year by the mean annual cost per
patient for each type. The costs for existing cases of
unknown type were estimated using the weighted average
costs for recurrent and resistant cases based on the
observed proportions. The total annual cost of genital
warts in Germany was then calculated as the sum of the
costs for the four types. The analysis was performed from
both the third-party payer (direct medical cost only) and
societal (direct medical cost and cost of lost productivity)
perspectives. The cost for specialist visits, diagnostic tests,
medication, and procedures were included in the direct
medical costs, and the cost of lost work days was consid-
ered in the indirect cost. The cost for retrospective and cur-
rent resource use was included in the costs for patients
with resistant and recurrent lesions. For patients with new
genital warts, the costs were based on the current visit and
the prescriptions by the physician during the consulta-
tion. The overall cost to third-party payers and the total
societal cost included both women and men, and all spe-
cialists.
Results
Incidence of genital warts
Between January and March 2005, 401 specialists were
invited by telephone to participate in the epidemiological
survey on genital warts. Of these, 217 agreed to partici-
pate: 135 gynecologists, 55 dermatologists, and 27 urolo-
gists. Data for 848 patients with genital warts were
collected for the study, including 508 new patients (inci-
dent) and 340 patients with existing genital warts (168
recurrent, 42 resistant, and 130 status unknown) (Table
2A). The majority of the patients were women (71%) and
most (86%) consulted a gynecologist for their genital
warts. Men consulted a dermatologist (61%) more often
than an urologist for genital warts (39%). Table 2B shows
the age-specific incidence of genital warts in women con-
sulting gynecologists. The overall incidence for new cases
was 113.7 (95% CI: 108.6–118.7) per 100 000 for women
aged 14–65 and 76.0 (95% CI: 72.6–79.4) per 100 000 of
the total female population. The overall incidence forBMC Infectious Diseases 2008, 8:76 http://www.biomedcentral.com/1471-2334/8/76
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recurrent cases was 34.7 (95% CI: 32.1–37.4) per 100 000
for women aged 14–65 and 23.2 (95% CI: 21.4–25.0) per
100 000 of the total female population. The highest age
stratified incidence for new cases was observed in women
aged 14–25 years (171.0 [95% CI: 163.4–178.5] per 100
000) while for recurrent cases it was higher in women
aged 26–45 years (53.1 [95% CI: 49.0–57.2] per 100
000). The number of males visiting dermatologists or
urologists was too limited to provide a meaningful inci-
dence of genital warts in this group. However, the
observed numbers of men with genital warts during the
study period were used in the extrapolation to approxi-
mate the total number of cases (male and female) of gen-
ital warts seen by physicians in Germany (Table 3). Using
the observed numbers (Table 2A) we estimated that there
were 54,358 new, 16,520 recurrent, 3982 resistant, and
14,193 existing (status unknown) cases of genital warts in
Germany, annually (Table 3).
Resources use and cost analysis
A total of 214 physicians participated in the chart review
study, including 129 gynecologists, 59 dermatologists,
and 26 urologists. More than 90% of the specialists were
office-based, and the others were based in hospitals. Most
of the specialists (85%) worked in their own medical prac-
tice. Data for 621 patients were collected; data for four of
these patients were excluded because they did not meet
the age criteria (n = 3) or had a treatment duration of over
12 months (n = 1).
Patient characteristics
The study sample (n = 617 patients) included 384 women
(62%) and 233 men (38%). The mean age was 32.0 ±
Table 1: Unit cost for resources used in the management and treatment of genital warts
Resource Unit cost (euros)
Outpatient visitsa Basic visit 19.37
Office-based treatmentsa Cryotherapy, electrosurgery, laser therapy 19.37
Curettage 86.59
Trichloroacetic acid 38.37
Diagnostic testsa,b Acetic acid tests/solcoderman 38.37
Anoscopy/proctoscopy 8.86
Biopsy 86.59
Colposcopy 4.25
Histological examination 26.34
Hybrid capture II (HPV DNA test) 40.00
Pap smear 5.42
Polymerase chain reaction (HPV PCR) 16.40
Urethroscopy/meatoscopy (men) 47.46
Urethroscopy/meatoscopy (women) 29.44
Visual examination 0
Hospital-based treatmentsc Colposcopy 1,490.60
Curettage, biopsy 1,252.80
Electosurgery or laser therapy (men) 1,403.60
Electosurgery or laser therapy (women) 1,464.50
Proctoscopy (men) 1,403.60
Proctoscopy (women) 1,490.60
Urethroscopy 1,403.60
Medications d Aldara® 5% cream 99.78
Condylox® solution 35.26
Solcoderman 38.37
Triapten (2 g) 16.91
Triapten (6 g) 45.00
Virudermin gel 4.85
Wartec® cream 0.15% 39.50
Indirect cost Lost work day (GDP/person/day)e 118.89
aEinheitliche Bewertungsmasstab (EBM) [16]. bGebührenordnung für Ärzte (GOA) [17]. cGerman Diagnosis Related Groups [18].dGelbe Liste 
Pharmindex [19]. eCalculated as: Gross domestic product (GDP) for Germany in 2004 (2207 billion euros)/population in 2004 (82,500,705; and 
number of working days per year (225) [15, 20, 21].BMC Infectious Diseases 2008, 8:76 http://www.biomedcentral.com/1471-2334/8/76
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10.0 years. There was no significant difference in age
between the patients with new (32.2 ± 10.1 years) and
existing (31.6 ± 9.9 years) genital warts. Treatment follow-
up time was not available for 12 of the 189 patients with
existing genital warts. The remaining 177 patients had a
mean follow-up of 6.7 ± 4.3 months. Approximately half
(48%) of the patients in the study had an elementary or
primary school education, 28% had a secondary or high
school education, and 12% had a college or postgraduate
degree. Of the 352 patients with data available, the major-
ity (95%) reported having had three or fewer new sexual
partners in the previous year: 13.9% had no new partner,
52.0% had one new partner, 20.7% had two new partners
and 7.9% had three new partners and 5.5% had more
than three new partners. Most of the patients (76%)
reported that they had not had a sexually transmitted
infection previously.
Clinical data
Sixty-nine percent (n = 428) of the patients were newly
diagnosed with genital warts; 15% had recurrent genital
warts (n = 92), 6% had resistant genital warts (n = 36) and
for 10% (n = 61) the type of existing genital warts was not
specified (Table 4). Almost all the patients (95%) had acu-
minate warts, but due to the diagnostic similarities
between the different types of warts, some physicians
Table 2: 
A. Observed numbers of men and women with genital warts seen annually by physicians included in the study
New Recurrent Resistant Unknown (existing) Total
Men Women Men Women Men Women Men Women Men Women
Gynecologists 0 303 0 104 0 29 0 95 0 531
Dermatologists 87 55 29 18 7 5 16 11 139 89
Urologists 63 0 17 0 1 0 8 0 89 0
Sub-total 150 358 46 122 8 34 24 106 228 620
Total 508 168 42 130 848
B. Age-specific incidence of genital warts in women consulting gynecologists
Incidence per 100 000 (95% CI)
Age (years) New genital warts Recurrent genital warts
14–25 171.0 (163.4–178.5) 52.8 (48.7–56.8)
26–45 156.5 (149.5–163.4) 53.1 (49.0–57.2)
46–65 36.3 (34.7–37.9) 5.0 (4.6–5.3)
14–65a 113.7 (108.6–118.7) 34.7 (32.1–37.4)
All ages 76.0 (72.6–79.4) 23.2 (21.4–25.0)
aThe total at-risk population (14–65 years of age).
Table 3: Estimated numbers of men and women with genital warts seen annually by physicians in Germany
New cases (95% CI) Recurrent cases (95% CI) Resistant cases (95% CI) Existing cases (unknown type) 
(95% CI)
Men Women Men Women Men Women Men Women
Gynecologists - 31,958 
(29,180–34,738)
- 9,768 
(8,291–11,245)
-3 , 0 1 3  
(2,102–3,925)
- 10,812 
(8,981–12,643)
Dermatologists 7,721 
(7,050–8,392)
4,937 
(3,962–4,716)
2,454 
(2,082–2,825)
1,569 
(1,331–1,806)
556 
(388–724)
355 
(248–463)
1,430 
(1,188–1,672)
914 
(759–1,069)
Urologists 9,742 
(8,895–10,589)
- 2,729 
(2,116–3,142)
- 58 
(40–75)
- 1,037 
(862–1,213)
-
Total 17,463 
(15,944–18,982)
36,895 
(33,687–40,103)
5,183 
(4398–5966)
11,337 
(9622–13,050)
614 
(428–780)
3,368 
(2,350–4,388)
2,467 
(2,049–2,887)
11,726 
(9,741–13,712)BMC Infectious Diseases 2008, 8:76 http://www.biomedcentral.com/1471-2334/8/76
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included patients with papular warts (4%), macular
lesions (0.3%), or a combination of acuminate warts and
other types of warts (0.5%). Most patients (74%) had
external lesions, 21% had both internal and external
lesions and 5% had only internal lesions. External lesions
in women included lesions on the following anatomical
sites: fourchette, labia minora and majora, clitoris, ure-
thral meatus, perineum, anal area, vestibule, introitus
(vaginal orifice), and vagina. Internal lesions were found
on the ectocervix. Fifty-seven percent of all women had
genital warts on the perineum, followed by the introitus
(35%), labia minora (35%), anal area (35%), labia
majora (34%), and vagina (21%). Only a few women
were reported to have lesions on the ectocervix (8%).
External lesions in males included lesions on the follow-
ing sites: glans, coronal sulcus, fraenulum, foreskin, scro-
tum, groin, perineum, anal area, penile shaft, and meatus.
Internal lesions were located in the urethra. In males, the
shaft of the penis was often affected by genital warts
(41%), followed by the glans (30%), the coronal sulcus
(28%), foreskin (24%), anal area (21%), fraenulum
(19%) and scrotum (12%). Only a few men were reported
to have lesions on the groin (6%), perineum (5%) or ure-
thra (4%).
Resource use by the patients
Of the 428 patients consulting a specialist for new genital
warts 254 (59%) saw a gynecologist, 117 (27%) a derma-
tologist, and 57 (13%) an urologist (Table 4). Of the 189
patients consulting for existing genital warts, 106 (56%)
consulted a gynecologist, 69 (37%) a gynecologist, and 14
(7%) an urologist at least once during the one-year data
collection period. The patients with existing genital warts
of unknown status (n = 61) were not included in the
resource use analysis. New patients had no retrospective
resource use as they were included in the study on their
first visit for a genital wart episode. Patients with existing
genital warts had a mean follow-up of 6.71 ± 4.29 months
and most had up to five consultations during this period.
The mean number of visits per year was slightly higher for
patients with resistant genital warts than for other types of
cases (data not shown).
For patients with new genital warts (n = 428) the most fre-
quent diagnostic tests were visual examination (36.7%),
Pap smear tests (15.7%), colposcopy (12.6%) and biopsy
(10.7%). For those with recurrent (n = 92) and resistant
genital warts (n = 36) visual examination was by far the
most frequent diagnostic test (94.6% and 97.2% respec-
tively), followed by Pap smear tests (32.6%), and biopsy
and colposcopy (26.1% for each) and 19.6% had histo-
logical tests. Imiquimod, podophyllotoxin solution, and
podophyllotoxin cream were the most frequently self-
administered medications for all patients (data not
shown). There was no difference in the frequency of use of
these therapies for new, recurrent, and resistant genital
warts. Table 5 shows the distribution of physician-admin-
istered therapies for patients with new, recurrent, and
resistant genital warts. The most common therapy for
patients with new and recurrent lesions was electrosurgery
(19.2% and 31.5%, respectively) compared with cryother-
apy (33.3%) for those with resistant lesions. More than
one-third of the patients, regardless of their type of lesion,
did not have a procedure at the physician's office at the
time of the visit. Almost 35% of patients with recurrent
genital warts and 30% of those with resistant genital warts
experienced adverse events after treatment. The main
reported adverse events were burning, skin reactions and
pain in the warts area. The percentage of patients with
recurrent and resistant genital warts who were hospital-
ized was 10.9% and 19.4%, respectively, with a median of
one hospitalization per patient (maximum 3 and 2,
respectively). Patients hospitalised for resistant warts (n =
7) and for recurrent warts (n = 10) had an average length
of stay of 5 days and 3 days, respectively (median 4 days
and 1 day) The median number of sick leave days was sim-
ilar for patients with recurrent genital warts (6 days –
range 1–5) and with resistant genital warts (7 days – range
3–14), but 25% of patients with resistant genital warts
took sick leave compared with 14.1% of those with recur-
rent warts.
Table 4: Distribution of patients included in the chart review survey
New cases  Existing cases
Recurrent Resistant Unknown type
Women Men Women Men Women Men Women Men Total
Gynecologist 253 1 53 0 14 0 39 0 360
D e r m a t o l o g i s t 1 5 1 0 2 22 551 731 7 186
Urologist 0 57 0 12 0 0 0 2 71
Sub-total  268 160 55 37 19 17 42 19
Total 428 92 36 61 617BMC Infectious Diseases 2008, 8:76 http://www.biomedcentral.com/1471-2334/8/76
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Estimated mean cost per patient with genital warts in Germany
All costs were highest for resistant genital warts: 1,141.8
euros (95% CI: 639.6–1752.3) for the mean annual direct
cost and 1,369.8 euros (95% CI: 830.1–1979.1) including
indirect costs. Direct mean cost for recurrent genital warts
were 602.7 euros (95% CI: 436.5–814.5) and 732.91
euros (95% CI: 514.6–961.9), including indirect costs
and 377.6 euros (95% CI: (310.75–444.88) for new geni-
tal warts (included direct cost only). Table 6 shows the
estimated mean annual direct and indirect costs for
patients with new, resistant, and recurrent genital warts by
gender. No significant differences in the mean direct and
indirect costs were observed between men and women.
Estimated total annual cost of genital warts in Germany
The total estimated annual direct cost for new, recurrent,
resistant, and existing genital warts of unknown status in
Germany was 20.8 million euros, 10.0 million euros, 5.7
million euros, and 12.0 million euros, respectively.
Including indirect costs the total expenditures rose to 12.7
million euros, 6.7 million euros, and 14.1 million euros
for recurrent, resistant, and existing genital warts of
unknown status, respectively. On the basis of these calcu-
lations, the total annual cost of genital warts in Germany
was estimated at 49.0 million euros from a third-party
payer perspective (indirect costs excluded) and 54.1 mil-
lion euros from a societal perspective (indirect costs
included), corresponding to an average cost per patient of
550 euros and 607 euros, respectively.
Multivariable analysis
Multivariable analyses identified the type of patient (new
versus existing), type of wart, and location of wart (inter-
nal, external, or both) as factors significantly affecting the
total cost of genital warts (P < 0.05) (Table 7). Gender, age
of patient, and type of specialist did not have a significant
impact on the total costs. With this model we calculated
the difference in the mean costs for different types of
patients, adjusted for the other cofactors. The models
showed that existing patients had, on average, an addi-
tional cost of 284 euros (95% CI: 88 – 479) compared
with new patients. Furthermore, the cost for patients with
only external warts was, on average 300 euros (95%CI:
132 – 468) lower than that for those with internal and
Table 5: Frequency of use of office therapies (procedures) for genital warts
New genital warts (n = 428) Recurrent genital warts (n = 92) Resistant genital warts (n = 36)
Procedure % Mean (SD) % Mean (SD) % Mean (SD)
None 38.3 50.0 44.4
Condylox/Phodophylotoxin Iocal/
Podophlin solution
5.1 1.2 (0.6) 12.0 1.7 (1.2) 25.0 2.0 (0.5)
Cryotherapy 7.2 2.7 (2.2) 13.0 2.3 (1.4) 33.3 3.2 (3.0)
Curettage 5.1 1.2 (0.5) 9.8 1.8 (1.1) 13.9 1.6 (0.9)
Electrosurgery 19.2 1.3 (1.1) 31.5 1.7 (1.1) 22.2 2.0 (1.4)
Excision 1.4 1.0 (0.0) 5.4 1.0 (0.0) 2.8 1.0 (0.0)
Laser therapy 14.0 1.0 (0.1) 15.2 1.3 (0.5) 25.0 1.2 (0.4)
Radiation therapy 0.0 - 1.1 6.0 (0.0) 2.8 6.0 (0.0)
Solcoderman 2.8 1.3 (0.6) 1.1 4.0 (0.0) 2.8 4.0 (0.0)
Surgery 0.0 - 1.1 1.0 (0.0) 5.6 2.0 (1.4)
Trichloroacetic acid 8.2 2.9 (2.1) 9.8 2.1 (1.5) 13.9 3.2 (2.1)
Other (not specified) 1.2 1.8 (1.3) 1.1 1.0 (0.0) 2.8 3.0 (0.0)
Table 6: Mean direct and indirect annual costs (euros) per patient with genital warts by gender
New cases Recurrent cases Resistant cases
Women n = 268 Men n = 160 Women n = 55 Men n = 37 Women n = 19 Men n = 17
Specialist visits 19.37 (19.37–19.37) 19.37 (19.37–19.37) 85.58 (67.27–111.29) 60.95 (52.35–69.63) 96.59 (69.32–134.57) 83.13 (67.23–100.27)
Diagnostics 132.18 (79.54–193.05) 63.38 (27.12–106.48) 269.43 (76.26–527.44) 56.22 (12.19–128.34) 580.36 (64.13–1,229.11) 47.00 (15.75–85.46)
Medications 44.06 (35.23–54.25) 47.11 (36.41–59.98) 90.61 (61.44–120.09) 74.84 (39.42–113.22) 153.66 (76.79–239.57) 100.38 (26.40–193.69)
Procedures 217.93 (155.97–285.22) 185.60 (123.85–257.39) 286.22 (133.57–466.95) 242.04 (54.57–488.61) 731.95 (342.32–1,180.28) 469.09 (42.64–1,156.60)
Total direct costs* 413.55 (322.33–506.05) 315.46 (235.33–407.13) 731.84 (475.80–1,046.71) 434.05 (230.33–695.47) 1,562.55 (841.52–
2,428.22)
699.60 (228.15–1,431.37)
Sick leave - - 142.07 (48.06–257.45) 115.57 (19.83–238.00) 231.67 (79.33–426.42) 203.87 (21.00–451.50)
Total cost (direct and 
indirect)
413.55 (322.33–506.05) 315.46 (235.33–407.13) 865.99 (575.18–1,219.90) 547.51 (283.35–874.30) 1,784.53 (988.26–
2,662.98)
903.47 (325.65–1,710.29)BMC Infectious Diseases 2008, 8:76 http://www.biomedcentral.com/1471-2334/8/76
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external warts. Lastly, patients with resistant warts spent
on average 424 euros (95% CI: 64 – 785) more for the
treatment of their warts.
Discussion
The incidence of genital warts was 171/100 000 in 14–25
year old women and 157/100 000 in 26–45 year old
women. This study confirms that genital warts are very
prevalent in young to mid-adult women in Germany. Fur-
thermore, the results indicate an annual health and eco-
nomic burden to the German health care system of at least
89 000 cases of genital warts and 54 million euros in asso-
ciated costs.
The overall incidence of new genital warts estimated for
Germany is lower than those reported in women in the
United Kingdom and France [9,22]. Results in the United
Kingdom showed an overall incidence of genital warts in
women of 122 per 100 000 population compared with 76
per 100 000 in this study [9]. The peak incidence
(reported in 16–19 year olds) was 703 per 100 000 popu-
lation compared with 171 per 100 000 in 14–25 year olds
in the present study. A direct comparison of these findings
is difficult because of the different methodologies used in
the studies. In the United Kingdom, data were obtained
for one year in an ongoing well-established genital warts
surveillance system, while our results were obtained
through a cross-sectional study over a two-month period
using a convenient sample of physicians [9]. Our esti-
mates are also lower than those reported in a study in
France that used similar methodology [22]. In this latter
study with a convenient sample of 212 gynecologists the
incidence reported was 176 and 48 per 100 000 females
aged 15 to 65 years old for new cases and recurrent cases,
respectively. Differences in HPV prevalence in Germany,
France and the UK may account for some of the disparity,
but we cannot rule out that the incidence of genital warts
has been underestimated in the present study. A reliable
estimate of the incidence of genital warts in males could
not be calculated because data were not available for a suf-
ficient number of men. However, despite the small sam-
ple size and the inherent limitations associated with small
sample sizes (e.g. higher margins of error in the estimate),
we used all the data collected in the epidemiological sur-
vey for the resource consumption part of the study to
obtain an estimate of the total number of cases (male and
female) of genital warts per year in Germany.
A report on the management of genital warts in the UK
estimated that the mean direct cost per new and recurrent
patient was £180 (266 euros) and £229 (338 euros),
respectively [23]. In The Netherlands, the mean cost for an
episode of care was 221 euros for men and 292 euros for
women [24]. These costs are lower then the mean direct
cost reported in the current study (550 euros). Another
recent cost analysis in France found that the estimated
mean annual direct costs per patient with new, recurrent,
and resistant genital warts were 416 euros, 620 euros, and
970 euros, respectively [22]. These results are similar to
those of the current study for new and recurrent genital
warts but the cost of resistant genital warts is lower in
France.
The study has several limitations. Although the physicians
who participated in this study were representative in terms
of geographic distribution and type of practice (90% were
office-based, 85% worked in the private sector) we cannot
exclude that physicians who did not participate were more
or less likely to see patients with genital warts. Also some
of the physicians participating in the study reported no
patients consulting for genital warts during the 2-month
study period and some could not provide an accurate esti-
mate of the number of patients with genital warts in their
practice. In addition, we could not verify if the patients
with genital warts seen by the physicians participating in
the study were representative out of all patients with gen-
Table 7: Results from the multivariable model (significant co-factors only)*
Variables Levels Estimate 95% CI P value
Type of patients Existing patients 284.17 88.85 479.49 0.0044
New patients (referent) 0.0 . .
Type of warts External -300.43 -468.21 -132.64 0.0005
Internal 238.40 -98.65 575.446 0.1653
Internal and external (referent) 0.0 . .
Infection status First infection -33.75 -243.84 176.35 0.7525
Recurrent infection -37.16 -313.82 239.50 0.7920
Resistant infection 424.13 63.77 784.50 0.0211
Unknown (referent) 0.0
* The analyses were adjusted for gender of the patient and type of specialist that treated the genital warts;BMC Infectious Diseases 2008, 8:76 http://www.biomedcentral.com/1471-2334/8/76
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ital warts in Germany. In addition, we assumed that all
patients with genital warts consult a physician; however,
it is possible that some patients with genital warts decided
not to seek medical care because they do not consider that
the condition is serious enough to seek medical care. If so,
ascertainment bias may have resulted in an underestima-
tion of the true incidence of genital warts in our study.
Our results show the incidence of patients seeking medi-
cal care for genital warts. These biases may have resulted
in either an over- or underestimation of the true incidence
of genital warts in Germany.
A second limitation is the extrapolation of the total
number of men with genital warts. The incidence of geni-
tal warts in men visiting dermatologists or urologists was
not calculated because too few data on males with genital
warts were available to provide a reliable estimate of the
incidence. From data obtained from the genital warts sur-
veillance system in the UK it is known that the incidence
for genital warts is comparable for men (146 per 100 000
population) and women (122 per 100 000 population)
[10]. Therefore, the total number of male genital warts
cases in Germany may be underestimated.
Lastly, our estimate of the total cost of genital warts in
Germany is likely to be underestimated. Annual resource
consumption data was collected only for existing patients.
For new patients, only the costs related to the first visit
were included, and no indirect costs were included. More-
over, the estimated number of men with genital warts is
likely to be underestimated, resulting in an underestima-
tion of the associated cost.
Recent results from clinical trials of prophylactic vaccina-
tion of women between 16 and 24 years of age with a
quadrivalent HPV (types 6,11,16,18) L1 virus-like particle
vaccine (Gardasil) have shown 100% vaccine efficacy for
the co-primary composite endpoints; incidence of genital
warts, vulvar or vaginal intraepithelial neoplasia or cancer
and incidence of cervical intraepithelial neoplasia, adeno-
carcinoma in situ or cancer associated with HPV type 6,
11, 16 or 18 (per-protocol susceptible population) [25].
This vaccine (Gardasil) was approved by the European
Medicines Agency and the US Food and Drug Administra-
tion in 2006 for the prevention of high-grade dysplasia of
the cervix or vulva, cancer of the cervix, and genital warts.
Since more than 90% of genital warts cases are associated
with infection by HPV types 6 and 11, our results suggest
that a vaccination programme using Gardasil should
reduce the medical and societal costs associated with gen-
ital warts management in Germany.
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